Drug intelligence / Profile preview

NNC0491-6075

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Small Molecules
Administration: Subcutaneous, Intravenous

Overview

NNC0491-6075 is an investigational drug developed by Novo Nordisk for the treatment of dyslipidaemia and high cholesterol. It is currently in early-stage clinical development (Phase 1). The drug acts as an inhibitor of angiopoietin-like protein 3 (ANGPTL3), a target known to play a role in lipid metabolism. By inhibiting ANGPTL3, NNC0491-6075 aims to lower levels of fat in the blood, particularly non-HDL cholesterol, which may help reduce cardiovascular risk. The drug is being evaluated for safety and pharmacokinetics in healthy volunteers and individuals with elevated blood lipids through subcutaneous or intravenous administration.

Other names: NN-6491NN6491NN 6491NNC0491 6075NNC-0491 6075NNC 0491 6075

Targets

ANGPTL3 (Angiopoietin-like protein 3)

Beyond the preview

Go deeper on NNC0491-6075.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0491-6075.

Explore the full profile